Abstract 528P
Background
Precision medicine has been increasingly practiced to select best-fit systemic treatment for advanced and metastatic (a/m) NSCLC. Though new treatment options help improve survival outcomes, they have led to increased financial burdens. In Hong Kong, limited financial assistance programs place the majority of treatment cost on patients. Our study aims to identify gaps in accessing standard-of-care (SOC) treatments and its determinants.
Methods
This prospective, territory-wide cohort study enrolled newly diagnosed a/m NSCLC patients from seven public oncology centers in Hong Kong since Mar 2021. Data on genomic landscape, treatment patterns and socioeconomic status (SES) of NSCLC patients were collected. Provision of SES data was voluntary. Patients were dichotomized into with or without druggable mutations. Proportion of patients receiving SOC were reported and analyzed in relation with SES parameters.
Results
Among 350 patients with SES data, 194 (55.5%) paid out-of-pocket costs for treatments, 110 (31.5%) were partially reimbursed by means-tested subsidy and 34 (9.7%) were fully reimbursed in employee remuneration package. Household income (HI) of 215 patients (60.9%) is less than 23000 USD/year, 95 (26.9%) between 23001-55300 USD/year, and 43 (12.1%) above 55301 USD/year. About 50% of patients had at least 2 children, lived with family members and received secondary education or above. For patients with druggable mutation (n=259), 152 (58.7%) received corresponding targeted treatments. In multivariate analyses (MVA), patients with HI >= 23001 USD/yr is significantly more likely to follow SOC than those with lower income. Self-financed patients are significantly more likely to receive targeted therapies than those with subsidy (OR: 3.73, p=0.004). For patients without druggable mutation (n=77), 32 (52%) received immunotherapy alone or combination. In MVA, patients with HI above 55301 USD/year are more likely to receive immunotherapy as part of treatment than those with lower income (OR: 11.90, p=0.08).
Conclusions
Patients with HI below 55301 USD/year is at risk of deprivation to accessing SOC treatment. Societal efforts are needed to secure equitable access to cancer treatment to all.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The University of Hong Kong.
Funding
Innovation and Technology Commission (HKSAR) & Roche.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
392TiP - A prospective phase II study of individualized adjuvant therapy in patients with locally advanced hypopharyngeal cancer after neoadjuvant therapy
Presenter: Juyi Wen
Session: Poster Display
Resources:
Abstract
397P - Comparison between Y-site co-infusion versus standard dexamethasone for preventing hypersensitivity reactions from oxaliplatin administration: A randomized controlled trial
Presenter: jarearnjit Phavirunsiri
Session: Poster Display
Resources:
Abstract
398P - Evaluation of the effectiveness of denosumab therapy giant cell tumor of the pelvis
Presenter: Abbos Nurjabov
Session: Poster Display
Resources:
Abstract
399P - Long-term outcomes of patients with gastric cancer who received the best supportive care without any anticancer treatment
Presenter: Yohei Arihara
Session: Poster Display
Resources:
Abstract
401TiP - Oral opioid vs intravenous patient-controlled analgesia (PCA) with hydromorphone bolus-only or continuous infusion to maintain analgesia for severe cancer pain: A randomized phase III trial
Presenter: Cheng Huang
Session: Poster Display
Resources:
Abstract
407P - K-TrackTM: A streamlined personalized assay to detect molecular residual disease in solid tumors
Presenter: Nam Vo
Session: Poster Display
Resources:
Abstract
408P - Increased EGFR and MET expression and corresponding tumor microenvironment (TME) change in hepatocellular carcinoma (HCC) tissues after sorafenib (Sora) treatment
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
410P - Systematic evaluation of cell-free DNA fragmentation patterns for cancer diagnosis and enhanced cancer detection through integration of multiple fragmentations
Presenter: Xiangy-Yu Meng
Session: Poster Display
Resources:
Abstract
412P - Multiplex digital spatial profiling (DSP) of protein reveals distinct immune and molecular phenotypes in hepatocellular carcinoma
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
413P - Clinical utility of advanced features provided by circulating tumor DNA-based comprehensive genomic profiling
Presenter: Young-gon Kim
Session: Poster Display
Resources:
Abstract